{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:27:20Z","timestamp":1783330040486,"version":"3.54.6"},"reference-count":262,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.pharmthera.2009.03.014","type":"journal-article","created":{"date-parts":[[2009,4,16]],"date-time":"2009-04-16T08:16:18Z","timestamp":1239869778000},"page":"187-206","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic role of sirolimus in non-transplant kidney disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Gopala K.","family":"Rangan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mainra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Succar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina G.","family":"Schwensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane S.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok On","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2009.03.014_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib2","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1172\/JCI26273","article-title":"The survival kinases Akt and Pim as potential pharmacological targets","volume":"115","author":"Amaravadi","year":"2005","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ki.1996.417","article-title":"Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506","volume":"50","author":"Andoh","year":"1996","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.ki.5001649","article-title":"Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine\u2013sirolimus interaction","volume":"70","author":"Anglicheau","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib5","series-title":"Davidson's principles and practice of medicine","first-page":"147","article-title":"Drug therapy","author":"Aronson","year":"2002"},{"issue":"7425","key":"10.1016\/j.pharmthera.2009.03.014_bib6","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","article-title":"Joining the DoTS: New approach to classifying adverse drug reactions","volume":"327","author":"Aronson","year":"2003","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.5414\/CPP44675","article-title":"Effects of sirolimus on proteinuria and renal function in focal segmental glomerulonephritis","volume":"44","author":"Aymanns","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","article-title":"Kidney-targeted Birt\u2013Hogg\u2013Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys","volume":"100","author":"Baba","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1992.tb06928.x","article-title":"Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice","volume":"89","author":"Baeder","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1046\/j.1523-1755.2003.00175.x","article-title":"Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy","volume":"64","author":"Bakker","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.phrs.2006.04.006","article-title":"Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients","volume":"54","author":"Baldan","year":"2006","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.1993.tb35856.x","article-title":"Rapamycin's inhibition of thymocyte proliferation, unlike that of cyclosporin A or prednisolone, is not associated with cytotoxicity","volume":"685","author":"Bansbach","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nm1291","article-title":"PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus","volume":"11","author":"Barber","year":"2005","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/cvr\/cvn024","article-title":"In human endothelial cells rapamycin causes mtorc2 inhibition and impairs cell viability and function","volume":"78","author":"Barilli","year":"2008","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2337\/db05-1576","article-title":"Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells","volume":"55","author":"Battaglia","year":"2006","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib17","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.pharmthera.2009.03.014_bib18","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1038\/sj.onc.1210243","article-title":"Cell-specific responses to loss of cyclin-dependent kinases","volume":"26","author":"Berthet","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/ndt\/gfm697","article-title":"Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease","volume":"23","author":"Berthier","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib20","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/S0041-1345(02)03574-1","article-title":"Effect of sirolimus on ischemia\/reperfusion injury in transgenic hypertensive rat","volume":"34","author":"Bohmova","year":"2002","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0962-8924(03)00169-7","article-title":"Role of polycystins in renal tubulogenesis","volume":"13","author":"Boletta","year":"2003","journal-title":"Trends Cell Biol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib22","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1681\/ASN.2004030180","article-title":"Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy","volume":"16","author":"Bonegio","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib23","first-page":"18A","article-title":"Factors contributing to the development of proteinuria after conversion from calcineurin inhibitors to sirolimus: results from the multicenter CONVERT Trial (abstract)","volume":"17","author":"Brennan","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"6483","key":"10.1016\/j.pharmthera.2009.03.014_bib24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib25","doi-asserted-by":"crossref","first-page":"F1397","DOI":"10.1152\/ajprenal.00133.2007","article-title":"Hypoxia and podocyte-specific Vhlh deletion confer risk of glomerular disease","volume":"293","author":"Brukamp","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/01.ftd.0000245377.93401.39","article-title":"Sirolimus\u2014Challenging current perspectives","volume":"28","author":"Buhaescu","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib27","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/ndt\/gfh957","article-title":"Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus","volume":"20","author":"Bumbea","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2003.09.003","article-title":"Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway","volume":"172","author":"Castro","year":"2004","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib30","first-page":"651","article-title":"Membranous nephropathy. Insights from Heymann nephritis","volume":"144","author":"Cavallo","year":"1994","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib31","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.transproceed.2007.09.008","article-title":"Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy","volume":"39","author":"Chapman","year":"2007","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2004100894","article-title":"Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy","volume":"16","author":"Chen","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1681\/ASN.2005111163","article-title":"Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy","volume":"17","author":"Chen","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1994.2140","article-title":"A putative sirolimus (rapamycin) effector protein","volume":"203","author":"Chen","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2133.2008.08903.x","article-title":"Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2","volume":"160","author":"Chen","year":"2009","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib37","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4049\/jimmunol.172.3.1355","article-title":"Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2\/Stat4 signaling pathway","volume":"172","author":"Chiang","year":"2004","journal-title":"J Immunol"},{"issue":"26","key":"10.1016\/j.pharmthera.2009.03.014_bib38","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1073\/pnas.91.26.12574","article-title":"RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12\/rapamycin complex","volume":"91","author":"Chiu","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/j.ajkd.2006.10.020","article-title":"Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity","volume":"49","author":"Cho","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/ajkd.2002.34544","article-title":"Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation","volume":"40","author":"Constantinescu","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib41","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/j.1523-1755.2005.00732.x","article-title":"Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy","volume":"68","author":"Coombes","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.tp.0000255680.71816.aa","article-title":"Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone","volume":"83","author":"Copeland","year":"2007","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib43","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.12-12-1404","article-title":"Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies","volume":"12","author":"Costa","year":"2007","journal-title":"Oncologist"},{"issue":"9163","key":"10.1016\/j.pharmthera.2009.03.014_bib44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(98)06195-9","article-title":"Glomerulonephritis","volume":"353","author":"Couser","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.ki.5002655","article-title":"Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts)","volume":"73","author":"D'Agati","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.transproceed.2007.01.031","article-title":"The effects of rapamycin in the progression of renal fibrosis","volume":"39","author":"Damiao","year":"2007","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib47","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/labinvest.3700078","article-title":"The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1","volume":"84","author":"Daniel","year":"2004","journal-title":"Lab Invest"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib48","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1111\/j.1600-6143.2005.01120.x","article-title":"Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat","volume":"5","author":"Daniel","year":"2005","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000020648","article-title":"Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative","volume":"8","author":"Daniel","year":"2000","journal-title":"Exp Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08923979309066932","article-title":"Functional and histopathologic effects of rapamycin on mouse kidney","volume":"15","author":"Di Joseph","year":"1993","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1 Pt 1","key":"10.1016\/j.pharmthera.2009.03.014_bib51","first-page":"714","article-title":"Influence of rat strain on rapamycin's kidney effects","volume":"25","author":"Di Joseph","year":"1993","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007890-199203000-00002","article-title":"The effect of rapamycin on kidney function in the Sprague\u2013Dawley rat","volume":"53","author":"Di Joseph","year":"1992","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib53","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1681\/ASN.2006030196","article-title":"Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?","volume":"17","author":"Di Paolo","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib54","first-page":"152","article-title":"Conversion to sirolimus for chronic allograft dysfunction: Long-term results confirm predictive value of proteinuria","volume":"21","author":"Diekmann","year":"2008","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib55","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1681\/ASN.2007010087","article-title":"Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass","volume":"18","author":"Diekmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nm1460","article-title":"Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice","volume":"12","author":"Ding","year":"2006","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib57","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1681\/ASN.V1071487","article-title":"Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states","volume":"10","author":"Dixon","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib58","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1432-2277.2002.tb00186.x","article-title":"Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up","volume":"15","author":"Ducloux","year":"2002","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib59","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1681\/ASN.V561273","article-title":"Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions","volume":"5","author":"Eddy","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib60","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2215\/CJN.05611207","article-title":"Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease","volume":"3","author":"Edelstein","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.pharmthera.2009.03.014_bib61","first-page":"8451","article-title":"Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells","volume":"63","author":"Edinger","year":"2003","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.pharmthera.2009.03.014_bib62","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"9366","key":"10.1016\/j.pharmthera.2009.03.014_bib63","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S0140-6736(03)13044-9","article-title":"Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma","volume":"361","author":"El-Hashemite","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib64","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":"Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice","volume":"3","author":"Elloso","year":"2003","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000101798","article-title":"Role of the VEGF\u2014A signaling pathway in the glomerulus: Evidence for crosstalk between components of the glomerular filtration barrier","volume":"106","author":"Eremina","year":"2007","journal-title":"Nephron Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib66","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","article-title":"Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival","volume":"17","author":"Eremina","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib67","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib69","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1046\/j.1523-1755.1999.00656.x","article-title":"Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro","volume":"56","author":"Fan","year":"1999","journal-title":"Kidney Int"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2009.03.014_bib70","doi-asserted-by":"crossref","first-page":"220S","DOI":"10.1016\/j.transproceed.2004.01.028","article-title":"Cyclosporine nephrotoxicity","volume":"36","author":"Fellstrom","year":"2004","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib71","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/ndt\/gfh079","article-title":"Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies","volume":"19","author":"Fervenza","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0002-9440(10)63659-0","article-title":"Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways","volume":"163","author":"Finckenberg","year":"2003","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib73","doi-asserted-by":"crossref","first-page":"F48","DOI":"10.1152\/ajprenal.00146.2004","article-title":"Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes","volume":"288","author":"Foster","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib74","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.TP.0000095897.38634.30","article-title":"Sirolimus delays recovery of rat kidney transplants after ischemia\u2013reperfusion injury","volume":"76","author":"Fuller","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib75","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.onc.1210721","article-title":"Defective TGF-beta signaling sensitizes human cancer cells to rapamycin","volume":"27","author":"Gadir","year":"2008","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.pharmthera.2009.03.014_bib76","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/93.20.1517","article-title":"Rapamycin's resurrection: A new way to target the cancer cell cycle","volume":"93","author":"Garber","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib77","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00007890-199412150-00002","article-title":"Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs","volume":"58","author":"Golbaekdal","year":"1994","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib78","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/sj.ki.5001893","article-title":"The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury","volume":"70","author":"Goncalves","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib80","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","article-title":"An expanding role for mTOR in cancer","volume":"11","author":"Guertin","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib81","first-page":"865A","article-title":"Dual effect of rapamycin on proteinuric experimental nephropathies. The Ying and the Yang (Abstract, PUB160)","volume":"18","author":"Gulias","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.03.014_bib82","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/ndt\/gfm084","article-title":"The role of proliferation signal inhibitors in post-transplant malignancies","volume":"22","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"10.1016\/j.pharmthera.2009.03.014_bib83","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"issue":"Pt 9","key":"10.1016\/j.pharmthera.2009.03.014_bib84","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1242\/jcs.01020","article-title":"Both mitogen activated protein kinase and the mammalian target of rapamycin modulate the development of functional renal proximal tubules in matrigel","volume":"117","author":"Han","year":"2004","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.47102\/annals-acadmedsg.V34N1p16","article-title":"Retardation of kidney failure\u2014Applying principles to practice","volume":"34","author":"Harris","year":"2005","journal-title":"Ann Acad Med Singapore"},{"issue":"5022","key":"10.1016\/j.pharmthera.2009.03.014_bib86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib87","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00467-004-1795-3","article-title":"Tuberous sclerosis and the kidney: From mesenchyme to epithelium, and beyond","volume":"20","author":"Henske","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"24","key":"10.1016\/j.pharmthera.2009.03.014_bib88","doi-asserted-by":"crossref","first-page":"13796","DOI":"10.1073\/pnas.241184198","article-title":"FRAP\/mTOR is required for proliferation and patterning during embryonic development in the mouse","volume":"98","author":"Hentges","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"30","key":"10.1016\/j.pharmthera.2009.03.014_bib89","doi-asserted-by":"crossref","first-page":"31948","DOI":"10.1074\/jbc.M400638200","article-title":"Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes","volume":"279","author":"Hleb","year":"2004","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib90","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1681\/ASN.2007121375","article-title":"Differential effects of rapamycin in anti-GBM glomerulonephritis","volume":"19","author":"Hochegger","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib91","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1054\/drup.2002.0227","article-title":"Mechanisms of resistance to rapamycins","volume":"4","author":"Huang","year":"2001","journal-title":"Drug Resist Updat"},{"issue":"14","key":"10.1016\/j.pharmthera.2009.03.014_bib92","doi-asserted-by":"crossref","first-page":"4917\u20144928","DOI":"10.1128\/MCB.23.14.4917-4928.2003","article-title":"Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling","volume":"23","author":"Huber","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"22","key":"10.1016\/j.pharmthera.2009.03.014_bib93","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib94","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4161\/cc.6.7.4047","article-title":"Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy","volume":"6","author":"Ibraghimov-Beskrovnaya","year":"2007","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib95","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0090-4295(03)00475-8","article-title":"Rapamycin preserves renal function compared with cyclosporine A after ischemia\/reperfusion injury","volume":"62","author":"Inman","year":"2003","journal-title":"Urology"},{"issue":"19","key":"10.1016\/j.pharmthera.2009.03.014_bib96","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJM200511103531922","article-title":"Post-transplantation proteinuria and sirolimus","volume":"353","author":"Izzedine","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.03.014_bib98","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0041-1345(00)02141-2","article-title":"Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury","volume":"33","author":"Jain","year":"2001","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib99","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients","volume":"19","author":"Johnston","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2009.03.014_bib100","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib101","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/00007890-200110150-00001","article-title":"Rapamycin: clinical results and future opportunities","volume":"72","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5414\/CNP63080","article-title":"Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus","volume":"63","author":"Kamar","year":"2005","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000123041","article-title":"FKBP family proteins: immunophilins with versatile biological functions","volume":"16","author":"Kang","year":"2008","journal-title":"Neurosignals"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib104","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1681\/ASN.V1271434","article-title":"Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1","volume":"12","author":"Kang","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib105","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib106","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf"},{"issue":"20","key":"10.1016\/j.pharmthera.2009.03.014_bib107","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1203\/01.PDR.0000147727.78571.07","article-title":"Effects of rapamycin in the Eker rat model of tuberous sclerosis complex","volume":"57","author":"Kenerson","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365510802150232","article-title":"Autoimmunity in kidney diseases","volume":"241","author":"Kettritz","year":"2008","journal-title":"Scand J Clin Lab Invest Suppl"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib110","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3349\/ymj.2004.45.6.1121","article-title":"Rapamycin inhibits platelet-derived growth factor-induced collagen, but not fibronectin, synthesis in rat mesangial cells","volume":"45","author":"Kim","year":"2004","journal-title":"Yonsei Med J"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib111","doi-asserted-by":"crossref","first-page":"F440","DOI":"10.1152\/ajprenal.00379.2007","article-title":"Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat","volume":"294","author":"Kramer","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib112","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00002018-200528020-00006","article-title":"Benefit\u2013risk assessment of sirolimus in renal transplantation","volume":"28","author":"Kuypers","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib113","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.pathol.1.110304.100119","article-title":"Pathogenesis of nonimmune glomerulopathies","volume":"1","author":"Kwoh","year":"2006","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib114","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1083\/jcb.200611146","article-title":"Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway","volume":"178","author":"Lamouille","year":"2007","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0022-3565(24)37526-3","article-title":"Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine","volume":"285","author":"Lampen","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"issue":"28","key":"10.1016\/j.pharmthera.2009.03.014_bib116","doi-asserted-by":"crossref","first-page":"20534","DOI":"10.1074\/jbc.M611782200","article-title":"Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif","volume":"282","author":"Land","year":"2007","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib117","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/01.tp.0000266555.06635.bf","article-title":"Sirolimus toxicity and vascular endothelial growth factor release from islet and renal cell lines","volume":"83","author":"Laugharne","year":"2007","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib118","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6604636","article-title":"mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?","volume":"99","author":"Le Tourneau","year":"2008","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib119","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1994.317","article-title":"Evidence that the inhibition of Na+\/K(+)-ATPase activity by FK506 involves calcineurin","volume":"46","author":"Lea","year":"1994","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1440-1797.2005.00493.x","article-title":"Sirolimus: Its role in nephrology","volume":"10","author":"Lee","year":"2005","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib121","doi-asserted-by":"crossref","first-page":"F617","DOI":"10.1152\/ajprenal.00278.2006","article-title":"A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy","volume":"292","author":"Lee","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.trre.2007.12.001","article-title":"mToR inhibitors-induced proteinuria: mechanisms, significance, and management","volume":"22","author":"Letavernier","year":"2008","journal-title":"Transplant Rev (Orlando)"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib123","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","article-title":"High sirolimus levels may induce focal segmental glomerulosclerosis de novo","volume":"2","author":"Letavernier","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib124","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfn574","article-title":"Sirolimus interacts with pathways essential for podocyte integrity","volume":"24","author":"Letavernier","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000225772.22757.5e","article-title":"Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance","volume":"82","author":"Lieberthal","year":"2006","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib126","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","article-title":"Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells","volume":"281","author":"Lieberthal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.transproceed.2006.01.026","article-title":"Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors","volume":"38","author":"Lisik","year":"2006","journal-title":"Transplant Proc"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib128","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.ki.5001543","article-title":"Rapamycin and chronic kidney disease: beyond the inhibition of inflammation","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib129","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1681\/ASN.2005050549","article-title":"Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats","volume":"17","author":"Lloberas","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib130","doi-asserted-by":"crossref","first-page":"F76","DOI":"10.1152\/ajprenal.00128.2006","article-title":"Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production","volume":"292","author":"Lock","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000257914.80918.72","article-title":"FK506 binding protein 12\/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure","volume":"49","author":"Long","year":"2007","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib132","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1097\/01.ASN.0000139932.00971.E4","article-title":"Ischemia\u2013reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin","volume":"15","author":"Loverre","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib133","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","article-title":"Rapamycin is an effective inhibitor of human renal cancer metastasis","volume":"63","author":"Luan","year":"2003","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib134","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib135","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1432-2277.2006.00361.x","article-title":"Effect of rapamycin on renal ischemia\u2013reperfusion injury in mice","volume":"19","author":"Lui","year":"2006","journal-title":"Transpl Int"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib136","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/ndt\/gfn216","article-title":"Rapamycin attenuates the severity of established nephritis in lupus-prone NZB\/W F1 mice","volume":"23","author":"Lui","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib137","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000166599","article-title":"Rapamycin attenuates the severity of murine adriamycin nephropathy","volume":"29","author":"Lui","year":"2008","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib138","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0961203307088289","article-title":"Rapamycin prevents the development of nephritis in lupus-prone NZB\/W F1 mice","volume":"17","author":"Lui","year":"2008","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib139","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1159\/000088400","article-title":"Cell cycle and glomerular disease: a minireview","volume":"102","author":"Marshall","year":"2006","journal-title":"Nephron Exp Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1139\/y77-007","article-title":"Inhibition of the immune response by rapamycin, a new antifungal antibiotic","volume":"55","author":"Martel","year":"1977","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib141","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ndt\/gfh639","article-title":"Nephrotoxicity of rapamycin: an emerging problem in clinical medicine","volume":"20","author":"Marti","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib142","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1681\/ASN.2006010039","article-title":"How much VEGF do you need?","volume":"17","author":"Mathieson","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib143","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","article-title":"Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation","volume":"3","author":"McTaggart","year":"2003","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib144","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.biocel.2004.02.002","article-title":"Regulation and role of autophagy in mammalian cells","volume":"36","author":"Meijer","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007890-200301150-00025","article-title":"Rapamycin impairs antigen uptake of human dendritic cells","volume":"75","author":"Monti","year":"2003","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2009.03.014_bib146","doi-asserted-by":"crossref","first-page":"154S","DOI":"10.1016\/S0041-1345(03)00224-0","article-title":"Tubular function in patients with hypokalemia induced by sirolimus after renal transplantation","volume":"35","author":"Morales","year":"2003","journal-title":"Transplant Proc"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2009.03.014_bib147","doi-asserted-by":"crossref","first-page":"52S","DOI":"10.1016\/S0041-1345(03)00244-6","article-title":"Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience","volume":"35","author":"Morelon","year":"2003","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib148","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1600-6143.2004.00446.x","article-title":"Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3\u00a0years","volume":"4","author":"Mota","year":"2004","journal-title":"Am J Transplant"},{"issue":"Pt 1","key":"10.1016\/j.pharmthera.2009.03.014_bib149","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1113\/jphysiol.2006.108324","article-title":"AMPK and cell proliferation\u2014AMPK as a therapeutic target for atherosclerosis and cancer","volume":"574","author":"Motoshima","year":"2006","journal-title":"J Physiol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.tp.0000240055.49572.07","article-title":"Sirolimus does not reduce receptor-mediated endocytosis of albumin in proximal tubule cells","volume":"83","author":"Mreich","year":"2007","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib151","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1523-1755.2005.00433.x","article-title":"Gas6 induces Akt\/mTOR-mediated mesangial hypertrophy in diabetic nephropathy","volume":"68","author":"Nagai","year":"2005","journal-title":"Kidney Int"},{"issue":"24","key":"10.1016\/j.pharmthera.2009.03.014_bib152","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib153","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0009-9120(96)00157-9","article-title":"Distribution of sirolimus in rat tissue","volume":"30","author":"Napoli","year":"1997","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib154","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000103918","article-title":"Effects of rapamycin on active Heymann nephritis","volume":"27","author":"Naumovic","year":"2007","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib155","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000087275","article-title":"Impaired glomerular and tubular function as a short-term effect of sirolimus treatment in the rat","volume":"25","author":"Nielsen","year":"2005","journal-title":"Am J Nephrol"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2009.03.014_bib156","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1113\/jphysiol.2006.122101","article-title":"Non-human primate fetal kidney transcriptome analysis indicates mammalian target of rapamycin (mTOR) is a central nutrient-responsive pathway","volume":"579","author":"Nijland","year":"2007","journal-title":"J Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib157","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/01.TP.0000128837.07640.AE","article-title":"Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin","volume":"78","author":"Ninova","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib158","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1096\/fj.04-2431fje","article-title":"Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty","volume":"19","author":"Nuhrenberg","year":"2005","journal-title":"Faseb J"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib159","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00007691-200410000-00001","article-title":"New insights into drug absorption: Studies with sirolimus","volume":"26","author":"Paine","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib160","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1523-1755.2005.00350.x","article-title":"Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability","volume":"67","author":"Pallet","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib161","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/157488606776930580","article-title":"Sirolimus early graft nephrotoxicity: Clinical and experimental data","volume":"1","author":"Pallet","year":"2006","journal-title":"Curr Drug Saf"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib162","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1472-8206.2008.00644.x","article-title":"Tacrolimus pharmacokinetic drug interactions: Effect of prednisone, mycophenolic acid or sirolimus","volume":"23","author":"Park","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib163","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/ndt\/gfh752","article-title":"Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report","volume":"20","author":"Patel","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib164","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","article-title":"Cell biology of the glomerular podocyte","volume":"83","author":"Pavenstadt","year":"2003","journal-title":"Physiol Rev"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1681\/ASN.2008050474","article-title":"Diabetes after transplantation and sirolimus: What's the connection?","volume":"19","author":"Pavlakis","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib166","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1681\/ASN.V1251059","article-title":"Pharmacokinetic interactions augment toxicities of sirolimus\/cyclosporine combinations","volume":"12","author":"Podder","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib167","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MNH.0b013e3282f5dbe4","article-title":"Focal segmental glomerulosclerosis: Recent advances","volume":"17","author":"Pollak","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib168","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1172\/JCI119038","article-title":"Rapamycin inhibits vascular smooth muscle cell migration","volume":"98","author":"Poon","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib169","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib170","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.ki.5002792","article-title":"Hypoxia stimulus: An adaptive immune response during dendritic cell maturation","volume":"73","author":"Rama","year":"2008","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib171","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-0012.2005.00366.x","article-title":"Chronic allograft nephropathy and nephrotic range proteinuria","volume":"19","author":"Ramanathan","year":"2005","journal-title":"Clin Transplant"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib172","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/0961203307081401","article-title":"Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment","volume":"16","author":"Ramos-Barron","year":"2007","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib173","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00002018-200629120-00006","article-title":"Sirolimus-associated proteinuria and renal dysfunction","volume":"29","author":"Rangan","year":"2006","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib174","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/ndt\/gfm191","article-title":"Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis","volume":"22","author":"Rangan","year":"2007","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib175","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib176","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1016\/j.transproceed.2005.05.029","article-title":"Combined use of tacrolimus and sirolimus in de novo renal transplant patients: current data","volume":"37","author":"Ribes","year":"2005","journal-title":"Transplant Proc"},{"issue":"13","key":"10.1016\/j.pharmthera.2009.03.014_bib177","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1074\/jbc.R000034200","article-title":"The TOR kinases link nutrient sensing to cell growth","volume":"276","author":"Rohde","year":"2001","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib178","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1681\/ASN.2007010125","article-title":"Genotype\u2013phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib179","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.transproceed.2007.06.054","article-title":"Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria","volume":"39","author":"Ruiz","year":"2007","journal-title":"Transplant Proc"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib180","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1093\/ndt\/gfl447","article-title":"Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction","volume":"21","author":"Ruiz","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib181","series-title":"Sirolimus: An expert panel guide on who and how to convert renal transplant patients from a CNI- to sirolimus-based regimen, including management of key adverse events (version 2). Sydney","author":"Russ","year":"2006"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib182","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1432-2277.2007.00547.x","article-title":"Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine","volume":"20","author":"Russ","year":"2007","journal-title":"Transpl Int"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib183","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/01.tp.0000178393.78084.9b","article-title":"Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function","volume":"80","author":"Russ","year":"2005","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib184","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ki.5002041","article-title":"The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states","volume":"71","author":"Russo","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib185","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: Insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib186","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib187","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1097\/00007890-200005150-00034","article-title":"Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat","volume":"69","author":"Sabbatini","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib188","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib189","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2005.12.012","article-title":"Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice","volume":"340","author":"Sakaguchi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib190","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib191","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib192","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib193","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2353\/ajpath.2007.070412","article-title":"Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin","volume":"171","author":"Sataranatarajan","year":"2007","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib194","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.transproceed.2007.06.031","article-title":"Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration","volume":"39","author":"Saurina","year":"2007","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib195","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ndt\/gfi266","article-title":"Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria","volume":"21","author":"Saurina","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib196","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2353\/ajpath.2007.060497","article-title":"Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin","volume":"170","author":"Schaefer","year":"2007","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib197","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1172\/JCI200112367","article-title":"Apoptosis in podocytes induced by TGF-beta and Smad7","volume":"108","author":"Schiffer","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib198","first-page":"648A","article-title":"Immunuosupressive drugs cause proapoptotic and antiapoptotic signaling response in podocytes (Abstract, SUPO298)","volume":"18","author":"Schonenberger","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib199","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"issue":"3 Suppl","key":"10.1016\/j.pharmthera.2009.03.014_bib200","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: Its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib201","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/j.1600-6143.2005.01013.x","article-title":"Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing","volume":"5","author":"Senior","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-8-13","article-title":"Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study","volume":"8","author":"Serra","year":"2007","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib203","first-page":"132A","article-title":"Efficacy, safety and tolerability of sirolimus in autosomal dominant polycystic kidney disease","volume":"19","author":"Serra","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.03.014_bib204","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/sj.ki.5000410","article-title":"The podocyte's response to injury: Role in proteinuria and glomerulosclerosis","volume":"69","author":"Shankland","year":"2006","journal-title":"Kidney Int"},{"issue":"22","key":"10.1016\/j.pharmthera.2009.03.014_bib205","doi-asserted-by":"crossref","first-page":"23166","DOI":"10.1074\/jbc.M401238200","article-title":"Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway","volume":"279","author":"Shegogue","year":"2004","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.pharmthera.2009.03.014_bib206","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/MCB.00290-07","article-title":"TOR signaling is a determinant of cell survival in response to DNA damage","volume":"27","author":"Shen","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/nano.2007.2.1.25","article-title":"Nanomedicines in renal transplant rejection\u2014Focus on sirolimus","volume":"2","author":"Shen","year":"2007","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.03.014_bib208","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1681\/ASN.2005111157","article-title":"Akt and Mammalian target of rapamycin regulate separate systems of proteolysis in renal tubular cells","volume":"17","author":"Shen","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib209","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000095300","article-title":"Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity","volume":"26","author":"Shihab","year":"2006","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib210","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.TP.0000116413.50765.F2","article-title":"Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1","volume":"77","author":"Shihab","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1523-1755.2004.00498.x","article-title":"Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity","volume":"65","author":"Shihab","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib212","first-page":"657A","article-title":"Effect of sirolimus, with and without cyclosporin, on apoptotic pathways (Abstract, FC-162)","volume":"16","author":"Shihab","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"10.1016\/j.pharmthera.2009.03.014_bib213","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib214","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000079734","article-title":"Induction sirolimus and delayed graft function after deceased donor kidney transplantation in the United States","volume":"24","author":"Simon","year":"2004","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib215","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2165\/00003495-200868050-00005","article-title":"Temsirolimus: In advanced renal cell carcinoma","volume":"68","author":"Simpson","year":"2008","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib216","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.ASN.0000057542.86377.5A","article-title":"Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use","volume":"14","author":"Smith","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib217","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1038\/sj.ki.5001948","article-title":"IL-1beta induces VEGF, independently of PGE2 induction, mainly through the PI3-K\/mTOR pathway in renal mesangial cells","volume":"70","author":"Sola-Villa","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib218","first-page":"123A","article-title":"Sirolimus therapy for patients with adult polycystic kidney disease\u2014A pilot study","volume":"19","author":"Soliman","year":"2008","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib219","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/01.ASN.0000102469.32182.8C","article-title":"Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function","volume":"15","author":"Stallone","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003088-200544080-00001","article-title":"Sirolimus: The evidence for clinical pharmacokinetic monitoring","volume":"44","author":"Stenton","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.03.014_bib221","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/sj.ki.5000122","article-title":"Post-transplantation nephrotic syndrome","volume":"69","author":"Stokes","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib222","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-6143.2005.01195.x","article-title":"Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism","volume":"6","author":"Straathof-Galema","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib223","first-page":"399A","article-title":"Inhibition of mTOR reduces crescent formation and improves renal function in experimental crescentic glomerulonephritis","volume":"18","author":"Succar","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib224","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s11427-008-0080-2","article-title":"Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines","volume":"51","author":"Sun","year":"2008","journal-title":"Sci China C Life Sci"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00007890-200201270-00033","article-title":"Rapamycin increases transforming growth factor-beta mRNA expression in immortalized rat proximal renal tubular cells","volume":"73","author":"Swinford","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib226","first-page":"24A","article-title":"Metformin activation of AMPK slows renal cystogenesis (abstract)","volume":"19","author":"Takiar","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib227","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib228","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.transproceed.2006.06.008","article-title":"Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy","volume":"38","author":"Teng","year":"2006","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.03.014_bib229","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1681\/ASN.2005050487","article-title":"Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus","volume":"16","author":"Teutonico","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib230","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007890-199502150-00021","article-title":"Effect of rapamycin on morphological and functional parameters in the kidney of the rabbit","volume":"59","author":"Thliveris","year":"1995","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib231","first-page":"417","article-title":"A comparison of the effects of rapamycin and cyclosporine on kidney and heart morphology in a rabbit heterotopic heart transplant model","volume":"10","author":"Thliveris","year":"1995","journal-title":"Histol Histopathol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib232","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/08923979309035233","article-title":"Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat","volume":"15","author":"Thomson","year":"1993","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib233","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.TP.0000101005.44661.3E","article-title":"Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery","volume":"77","author":"Tian","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib234","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2215\/CJN.00340107","article-title":"Sirolimus: Defining nephrotoxicity in the renal transplant recipient","volume":"2","author":"Tomlanovich","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9569","key":"10.1016\/j.pharmthera.2009.03.014_bib235","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2009.03.014_bib236","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","article-title":"Targeting mammalian target of rapamycin (mTOR) for health and diseases","volume":"12","author":"Tsang","year":"2007","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib237","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.00120605","article-title":"A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis","volume":"1","author":"Tumlin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.03.014_bib238","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.ki.5001792","article-title":"Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients","volume":"70","author":"van den Akker","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib239","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1152\/ajprenal.00181.2004","article-title":"Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts","volume":"289","author":"Varghese","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.03.014_bib240","first-page":"432","article-title":"Effect of sirolimus on renal ischaemia\/reperfusion injury in normotensive and hypertensive rats","volume":"17","author":"Viklicky","year":"2004","journal-title":"Transpl Int"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib241","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/01.tp.0000282866.92367.99","article-title":"The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat","volume":"84","author":"Vogelbacher","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib242","doi-asserted-by":"crossref","first-page":"C22","DOI":"10.1152\/ajpcell.00227.2007","article-title":"Proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells","volume":"294","author":"Vogetseder","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib243","doi-asserted-by":"crossref","first-page":"F418","DOI":"10.1152\/ajprenal.90319.2008","article-title":"mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes","volume":"296","author":"Vollenbroeker","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib244","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.03.014_bib245","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0041-1345(00)02320-4","article-title":"Effect of rapamycin and FK506 on mesangial cell proliferation","volume":"33","author":"Wang","year":"2001","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib246","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.pharmthera.2009.03.014_bib247","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1007\/BF01778335","article-title":"Sub-therapeutic doses of sirolimus and cyclosporin A in combination reduce SLE pathologies in the MRL mouse","volume":"44","author":"Warner","year":"1995","journal-title":"Inflamm Res"},{"issue":"21","key":"10.1016\/j.pharmthera.2009.03.014_bib248","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4161\/cc.5.21.3408","article-title":"Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?","volume":"5","author":"Weimbs","year":"2006","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib249","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.ki.5000065","article-title":"Kidney cancer: Identification of novel targets for therapy","volume":"69","author":"Weiss","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.03.014_bib250","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1053\/j.ajkd.2006.05.018","article-title":"Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex","volume":"48","author":"Wienecke","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib251","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biocel.2006.08.004","article-title":"Role of the phosphatidylinositol 3-kinase and mTOR pathways in the regulation of renal fibroblast function and differentiation","volume":"39","author":"Winbanks","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib252","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1159\/000116112","article-title":"The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat","volume":"108","author":"Wittmann","year":"2008","journal-title":"Nephron Exp Nephrol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.03.014_bib253","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00470.2007","article-title":"Are renal proximal tubular epithelial cells constantly prepared for an emergency? Focus on \u201cthe proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells","volume":"294","author":"Witzgall","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.03.014_bib254","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.03.014_bib255","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","article-title":"Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis","volume":"69","author":"Wu","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib256","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1111\/j.1523-1755.2005.00662.x","article-title":"Inflammation and caspase activation in long-term renal ischemia\/reperfusion injury and immunosuppression in rats","volume":"68","author":"Yang","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib257","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000106782","article-title":"Rapamycin prevents early steps of the development of diabetic nephropathy in rats","volume":"27","author":"Yang","year":"2007","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.03.014_bib258","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ki.1993.251","article-title":"CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC","volume":"44","author":"Yard","year":"1993","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib259","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/00007890-199311000-00029","article-title":"Blood distribution of rapamycin","volume":"56","author":"Yatscoff","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2009.03.014_bib260","first-page":"131A","article-title":"Sirolimus treatment in the female Han:Sprd (Cy\/+) rat model of PKD","volume":"19","author":"Zafar","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"46","key":"10.1016\/j.pharmthera.2009.03.014_bib261","doi-asserted-by":"crossref","first-page":"17272","DOI":"10.1073\/pnas.0608531103","article-title":"AMP-activated protein kinase regulates the assembly of epithelial tight junctions","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.03.014_bib262","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/art.22593","article-title":"Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus","volume":"56","author":"Zoja","year":"2007","journal-title":"Arthritis Rheum"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T23:57:49Z","timestamp":1739059069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":262,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0163725809000643"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.03.014","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}